Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy

Wang, ZC; Muthusamy, V; Petrylak, DP; Anderson, KS

Anderson, KS (通讯作者)，Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.;Anderson, KS (通讯作者)，Yale Univ, Sch Med, Dept Mol Biophys & Biochem, 333 Cedar St, New Haven, CT 06520 USA.

NPJ PRECISION ONCOLOGY, 2023; 7 (1):

Abstract

Bladder cancer (BC) is one of the most prevalent malignancies worldwide and FGFR3 alterations are particularly common in BC. Despite approval of erdaf......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索